Back to results
US 11,896,647 B2Granted
Methods of treating cognitive impairment
AssigneeUniversity of South Florida
InventorsHuntington Potter, Gary W. Arendash, Steven Bennett, Timothy Boyd
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of South Florida
InventorsHuntington Potter, Gary W. Arendash, Steven Bennett, Timothy Boyd
Estimating the term…
The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
A method for reducing the level of an amyloid beta (Aβ) peptide in the brain of a person or animal, comprising administering to the person or animal an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, wherein the level of an AP peptide is reduced in the person or animal relative to the level of AP peptide in the brain of the person or animal prior to administration of the GM-CSF.
A method for increasing the synaptic density in the CA1 or CA3 regions of the hippocampus of a person with Alzheimer's disease, comprising administering to the person an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, whereby the person exhibits increased synaptic density relative to the level of synaptic density in the CA1 or CA3 regions of the hippocampus of the person prior to administration of GM-CSF.
Dependencies are inferred from the claim text.